

In-Solution Kinetics by Fida Biosystems: Redefining Drug Interaction Analysis for Therapeutic Discovery

A Major Technological Milestone for Drug Discovery & Development: Fida Neo pioneers In-Solution Kinetics with no environmental constraints.

SØBORG, DENMARK, March 13, 2024 /EINPresswire.com/ -- Fida Biosystems

announced today a significant expansion to the capabilities of its proprietary Flow Induced Dispersion Analysis (FIDA) technology with the integration of in-solution kinetics. This enhancement comes with a launch of Fida Neo – the new generation of Fida

Instrument, and builds upon FIDA's established proficiency in affinity and quality assessments, reinforcing the technology's position at the forefront of biomolecular research. The latest advancement enables the direct determination of k_{on} and k_{off} in drug-target interactions within their native environments, devoid of the biases introduced by traditional immobilisation techniques.

“

Allows for a high-fidelity representation of biomolecular behaviors, facilitating identification of the optimal therapeutic candidates and potentially reducing the cost of subsequent clinical trials.”


Brian Sørensen

Brian Sørensen, CEO of Fida Biosystems, stated:

"The inclusion of in-solution kinetics into FIDA's analytical repertoire marks a pivotal evolution in our technology. This capability allows for a high-fidelity representation of biomolecular behaviors, facilitating earlier identification of the optimal therapeutic candidates and potentially reducing the cost of subsequent clinical trials."

The traditional assessment of drug-target interactions has

relied on immobilising one of the binding partners, often leading to non-specific binding and the need for laborious surface regeneration. Building on [Taylor Dispersion Analysis](#) in a microscale



In-solution kinetics delivered by Fida Neo increase the ability to study molecular interactions in clinically relevant settings

capillary system, FIDA offers a new direct-measurement based approach, which precisely controls reaction times via the manipulation of sample introduction in the capillary. This first-principle, immobilisation free method to in-solution analysis negates the environmental restrictions that have historically constrained biomolecular studies, such as buffer composition, temperature, and ionic strength.

With the FIDA 1 system [already established](#) as a robust tool for measuring affinity, quality, and quantity, the integration of in-solution kinetics further solidifies FIDA's role in the market as the most comprehensive solution for biophysics research across pharmaceutical, biotech, and academic sectors.

For more information on the impact of FIDA's in-solution kinetics on biomolecular interaction studies and therapeutic development, contact Brian Sørensen (brian@[fidabio.com](mailto:brian@fidabio.com)) or visit fidabio.com.

Brian Sørensen

Fidabio

+45 28192580

[email us here](#)

Visit us on social media:

[Twitter](#)

[LinkedIn](#)

[YouTube](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/693422772>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.